Computational Modeling-Based Discovery of Novel Classes of Anti-Inflammatory Drugs That Target Lanthionine Synthetase C-Like Protein 2

Background Lanthionine synthetase component C-like protein 2 (LANCL2) is a member of the eukaryotic lanthionine synthetase component C-Like protein family involved in signal transduction and insulin sensitization. Recently, LANCL2 is a target for the binding and signaling of abscisic acid (ABA), a plant hormone with anti-diabetic and anti-inflammatory effects. Methodology/Principal Findings The goal of this study was to determine the role of LANCL2 as a potential therapeutic target for developing novel drugs and nutraceuticals against inflammatory diseases. Previously, we performed homology modeling to construct a three-dimensional structure of LANCL2 using the crystal structure of lanthionine synthetase component C-like protein 1 (LANCL1) as a template. Using this model, structure-based virtual screening was performed using compounds from NCI (National Cancer Institute) Diversity Set II, ChemBridge, ZINC natural products, and FDA-approved drugs databases. Several potential ligands were identified using molecular docking. In order to validate the anti-inflammatory efficacy of the top ranked compound (NSC61610) in the NCI Diversity Set II, a series of in vitro and pre-clinical efficacy studies were performed using a mouse model of dextran sodium sulfate (DSS)-induced colitis. Our findings showed that the lead compound, NSC61610, activated peroxisome proliferator-activated receptor gamma in a LANCL2- and adenylate cyclase/cAMP dependent manner in vitro and ameliorated experimental colitis by down-modulating colonic inflammatory gene expression and favoring regulatory T cell responses. Conclusions/Significance LANCL2 is a novel therapeutic target for inflammatory diseases. High-throughput, structure-based virtual screening is an effective computational-based drug design method for discovering anti-inflammatory LANCL2-based drug candidates.

[1]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[2]  C. James,et al.  Lanthionine synthetase components C-like 2 increases cellular sensitivity to adriamycin by decreasing the expression of P-glycoprotein through a transcription-mediated mechanism. , 2003, Cancer research.

[3]  Stefano Costanzi,et al.  On the applicability of GPCR homology models to computer-aided drug discovery: a comparison between in silico and crystal structures of the beta2-adrenergic receptor. , 2008, Journal of medicinal chemistry.

[4]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[5]  Todd J. A. Ewing,et al.  DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases , 2001, J. Comput. Aided Mol. Des..

[6]  M. Leach,et al.  The Role of IL-10 in Inflammatory Bowel Disease: "Of Mice and Men" , 1999, Toxicologic pathology.

[7]  Ruben Abagyan,et al.  Discovery of diverse thyroid hormone receptor antagonists by high-throughput docking , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[8]  T. Naka,et al.  IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells , 2007, Proceedings of the National Academy of Sciences.

[9]  D. J. Price,et al.  Assessing scoring functions for protein-ligand interactions. , 2004, Journal of medicinal chemistry.

[10]  J. Bassaganya-Riera,et al.  Abscisic acid synergizes with rosiglitazone to improve glucose tolerance and down-modulate macrophage accumulation in adipose tissue: possible action of the cAMP/PKA/PPAR γ axis. , 2010, Clinical nutrition.

[11]  L. Sturla,et al.  Binding of abscisic acid to human LANCL2. , 2011, Biochemical and biophysical research communications.

[12]  Walter Filgueira de Azevedo,et al.  Protein crystallography in drug discovery. , 2008, Current drug targets.

[13]  J. Bassaganya-Riera,et al.  Abscisic acid ameliorates experimental IBD by downregulating cellular adhesion molecule expression and suppressing immune cell infiltration. , 2010, Clinical nutrition.

[14]  Emanuela Jacchetti,et al.  LANCL2 Is Necessary for Abscisic Acid Binding and Signaling in Human Granulocytes and in Rat Insulinoma Cells* , 2009, The Journal of Biological Chemistry.

[15]  J. Bassaganya-Riera,et al.  T cell PPARγ is required for the anti-inflammatory efficacy of abscisic acid against experimental IBD. , 2011, The Journal of nutritional biochemistry.

[16]  J. Bassaganya-Riera,et al.  Abscisic acid ameliorates atherosclerosis by suppressing macrophage and CD4+ T cell recruitment into the aortic wall. , 2010, The Journal of nutritional biochemistry.

[17]  J. Bassaganya-Riera,et al.  Molecular modeling of lanthionine synthetase component C-like protein 2: a potential target for the discovery of novel type 2 diabetes prophylactics and therapeutics , 2011, Journal of molecular modeling.

[18]  S. Snapper,et al.  Regulatory T cells in inflammatory bowel disease , 2008, Current opinion in gastroenterology.

[19]  Yanjun Liu,et al.  Structure of human lanthionine synthetase C-like protein 1 and its interaction with Eps8 and glutathione. , 2009, Genes & development.

[20]  Gerhard Klebe,et al.  Ligand-supported homology modeling of g-protein-coupled receptor sites: models sufficient for successful virtual screening. , 2004, Angewandte Chemie.

[21]  B. Sobral,et al.  Abscisic Acid Regulates Inflammation via Ligand-binding Domain-independent Activation of Peroxisome Proliferator-activated Receptor γ* , 2010, The Journal of Biological Chemistry.

[22]  Brian K. Shoichet,et al.  Virtual screening of chemical libraries , 2004, Nature.

[23]  J. Bassaganya-Riera,et al.  Mechanisms of action and medicinal applications of abscisic Acid. , 2010, Current Medicinal Chemistry.

[24]  J. Bassaganya-Riera,et al.  Loss of PPARγ in immune cells impairs the ability of abscisic acid to improve insulin sensitivity by suppressing monocyte chemoattractant protein-1 expression and macrophage infiltration into white adipose tissue , 2008 .

[25]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[26]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[27]  R. Prohaska,et al.  Myristoylation of human LanC-like protein 2 (LANCL2) is essential for the interaction with the plasma membrane and the increase in cellular sensitivity to adriamycin. , 2006, Biochimica et biophysica acta.

[28]  Didier Rognan,et al.  Protein‐based virtual screening of chemical databases. II. Are homology models of g‐protein coupled receptors suitable targets? , 2002, Proteins.

[29]  Torsten Schwede,et al.  The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling , 2006, Bioinform..

[30]  Xiaomin Luo,et al.  PDTD: a web-accessible protein database for drug target identification , 2008, BMC Bioinformatics.

[31]  F. Melo,et al.  Assessing protein structures with a non-local atomic interaction energy. , 1998, Journal of molecular biology.

[32]  J. Bassaganya-Riera,et al.  Dietary abscisic acid ameliorates glucose tolerance and obesity-related inflammation in db/db mice fed high-fat diets. , 2007, Clinical nutrition.

[33]  R. Prohaska,et al.  Molecular Cloning, Characterization, and Tissue-Specific Expression of Human LANCL2, a Novel Member of the LanC-Like Protein Family , 2001, DNA sequence : the journal of DNA sequencing and mapping.

[34]  Xiaomin Luo,et al.  TarFisDock: a web server for identifying drug targets with docking approach , 2006, Nucleic Acids Res..

[35]  Shao-heng He,et al.  IL-10 and its related cytokines for treatment of inflammatory bowel disease. , 2004, World journal of gastroenterology.

[36]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[37]  C. Usai,et al.  Abscisic Acid Is an Endogenous Stimulator of Insulin Release from Human Pancreatic Islets with Cyclic ADP Ribose as Second Messenger* , 2008, Journal of Biological Chemistry.

[38]  B. Rollins,et al.  Critical role of MCP-1 in the pathogenesis of experimental colitis in the context of immune and enterochromaffin cells. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[39]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[40]  J. Bassaganya-Riera,et al.  Loss of PPAR gamma in immune cells impairs the ability of abscisic acid to improve insulin sensitivity by suppressing monocyte chemoattractant protein-1 expression and macrophage infiltration into white adipose tissue. , 2008, The Journal of nutritional biochemistry.

[41]  J. Bassaganya-Riera,et al.  Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. , 2004, Gastroenterology.

[42]  J. Bassaganya-Riera,et al.  Activation of PPAR γ and δ by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease , 2004 .

[43]  F. Powrie,et al.  Regulatory T cells and inflammatory bowel disease. , 1999, Immunology today.

[44]  W. A. van der Donk,et al.  Biosynthesis and mode of action of lantibiotics. , 2005, Chemical reviews.

[45]  M. Neurath,et al.  Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. , 2007, Inflammatory bowel diseases.

[46]  A. Marchler-Bauer,et al.  Isolation, molecular characterization, and tissue-specific expression of a novel putative G protein-coupled receptor. , 1998, Biochimica et biophysica acta.